Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

144 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Endosomal escape pathways for delivery of biologicals.
Varkouhi AK, Scholte M, Storm G, Haisma HJ. Varkouhi AK, et al. J Control Release. 2011 May 10;151(3):220-8. doi: 10.1016/j.jconrel.2010.11.004. Epub 2010 Nov 13. J Control Release. 2011. PMID: 21078351 Review.
Targeted adenovirus mediated inhibition of NF-κB-dependent inflammatory gene expression in endothelial cells in vitro and in vivo.
Kułdo JM, Ásgeirsdóttir SA, Zwiers PJ, Bellu AR, Rots MG, Schalk JA, Ogawara KI, Trautwein C, Banas B, Haisma HJ, Molema G, Kamps JA. Kułdo JM, et al. J Control Release. 2013 Feb 28;166(1):57-65. doi: 10.1016/j.jconrel.2012.12.016. Epub 2012 Dec 20. J Control Release. 2013. PMID: 23266453
Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter.
Gommans WM, McLaughlin PM, Schalk JA, Groothuis GM, Haisma HJ, Rots MG. Gommans WM, et al. J Control Release. 2007 Jan 22;117(1):1-10. doi: 10.1016/j.jconrel.2006.10.006. Epub 2006 Nov 28. J Control Release. 2007. PMID: 17137670
Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors.
Rots MG, Curiel DT, Gerritsen WR, Haisma HJ. Rots MG, et al. J Control Release. 2003 Feb 21;87(1-3):159-65. doi: 10.1016/s0168-3659(02)00360-7. J Control Release. 2003. PMID: 12618032 Review.
Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ, Storm G, Hennink WE, Gerritsen WR, Haisma HJ. Fonseca MJ, et al. J Gene Med. 1999 Nov-Dec;1(6):407-14. doi: 10.1002/(SICI)1521-2254(199911/12)1:6<407::AID-JGM71>3.0.CO;2-Q. J Gene Med. 1999. PMID: 10753066
Towards a double controlled conditionally replicative adenovirus for potent and specific melanoma cell kill.
Gommans WM, Oosterhuis D, Dmitriev I, Schaack J, Curiel DT, Haisma HJ, Rots MG. Gommans WM, et al. J Control Release. 2006 Nov 28;116(2):e64-6. doi: 10.1016/j.jconrel.2006.09.052. J Control Release. 2006. PMID: 17718975 No abstract available.
Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
Vingerhoeds MH, Haisma HJ, Belliot SO, Smit RH, Crommelin DJ, Storm G. Vingerhoeds MH, et al. Pharm Res. 1996 Apr;13(4):604-10. doi: 10.1023/a:1016010524510. Pharm Res. 1996. PMID: 8710754
Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties.
Fonseca MJ, Haisma HJ, Klaassen S, Vingerhoeds MH, Storm G. Fonseca MJ, et al. Biochim Biophys Acta. 1999 Jul 15;1419(2):272-82. doi: 10.1016/s0005-2736(99)00073-5. Biochim Biophys Acta. 1999. PMID: 10407077
Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A.
Roy H, Bhardwaj S, Babu M, Jauhiainen S, Herzig KH, Bellu AR, Haisma HJ, Carmeliet P, Alitalo K, Ylä-Herttuala S. Roy H, et al. Hum Gene Ther. 2005 Dec;16(12):1422-8. doi: 10.1089/hum.2005.16.1422. Hum Gene Ther. 2005. PMID: 16390273
144 results
Jump to page
Feedback